Yatiri Bio Inc. was recently awarded a $110K Phase 1 grant from the prestigious Congressionally Directed Medical Research Programs (CDMRP) administered by the US Department of Defense. This grant will fund key development milestones for our platform in the field of hypopharyngeal cancer. Yatiri Bio will perform a global analysis of protein expression using proteomics in hypopharyngeal cancer biopsy samples.

This data will then be fed into our bioinformatics platform and using machine learning algorithms allow us to clearly define patient subtypes. To advance treatment options our ML platform will be used to match cellular model systems to these patient subsets. The model systems will be screened against a panel of FDA approved drugs to identify potential therapeutics for molecularly defined hypopharyngeal patient subsets. This data will be fed back into our bioinformatics platform to further optimize our models. Our goal is to then partner with pharmaceutical companies and assist them in either discovering new targets to treat hypopharyngeal cancer or identifying patient subtypes that are sensitive to their therapies.

The CDMRP’s mission is to advance medical and scientific research that will make a high impact on the health of service members, veterans, and their families. The CDMRP manages 29 research programs including several programs on behalf of the Department of Defense. More information about CDMRP can be found at https://cdmrp.health.mil/default